Laboratory Alliance of Central New York, LLC

Laboratory Alliance of Central New York, LLC was paid $10.56M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 11% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#21 of 116

Median peer was paid$618K

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	125,864	$1.00M
2019	159,761	$1.36M
2020	174,044	$1.70M
2021	202,970	$1.93M
2022	198,222	$1.79M
2023	182,684	$1.52M
2024incomplete	161,594	$1.25M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	11%	21,135	19,589	$1.11M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	4.5%	23,146	23,056	$474K
87631		4.5%	5,991	5,680	$471K
80053	Comprehensive metabolic panel	3.9%	63,588	58,823	$409K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	3.8%	22,676	22,440	$397K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	3.7%	22,702	22,464	$392K
84443	Thyroid stimulating hormone (TSH)	2.7%	44,817	44,325	$290K
88305	Level IV - Surgical pathology, gross and microscopic examination	2.7%	7,365	7,126	$284K
87086	Culture, bacterial; quantitative colony count, urine	2.4%	46,058	43,320	$250K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.3%	14,952	13,679	$239K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.2%	79,756	71,959	$228K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.9%	14,924	14,882	$199K

234 more codes

80061	Lipid panel	1.9%	38,545	$198K
86003		1.8%	5,278	$189K
87660		1.6%	15,917	$167K
86780		1.4%	16,604	$153K
87480		1.4%	13,612	$149K
84439		1.4%	24,914	$147K
83036	Hemoglobin; glycosylated (A1C)	1.3%	22,826	$142K
87510		1.3%	12,595	$137K
80050	General health panel	1.3%	5,281	$134K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.2%	6,700	$126K
87077		1.0%	16,025	$110K
87070		<1%	17,508	$104K
88142		<1%	6,357	$103K
80048	Basic metabolic panel (calcium, ionized)	<1%	21,612	$100K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	4,774	$100K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	5,984	$99K
82728		<1%	11,082	$97K
87340		<1%	12,276	$93K
87653		<1%	5,432	$93K
82607		<1%	10,933	$91K
86480		<1%	2,979	$89K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	7,398	$87K
83655		<1%	8,579	$81K
86803		<1%	10,880	$81K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	2,677	$80K
84403		<1%	4,239	$80K
86762		<1%	7,145	$73K
86618		<1%	6,144	$71K
87186		<1%	14,668	$70K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,692	$69K
87522	Neg quan hep c or qual rna	<1%	2,086	$68K
84702		<1%	7,183	$65K
86665		<1%	2,681	$63K
82670		<1%	3,107	$62K
87902		<1%	323	$56K
86850		<1%	12,022	$56K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	3,551	$51K
83001		<1%	3,696	$50K
83021		<1%	3,688	$50K
85027		<1%	21,319	$49K
82784		<1%	5,307	$49K
84146		<1%	3,272	$47K
83550		<1%	12,611	$44K
80076		<1%	8,195	$43K
83540		<1%	13,106	$42K
83970		<1%	1,606	$41K
84153		<1%	3,238	$41K
83002		<1%	3,009	$40K
85610		<1%	14,428	$39K
84144		<1%	2,607	$38K
86038		<1%	7,672	$38K
87506		<1%	561	$37K
86140		<1%	12,643	$37K
83880		<1%	1,883	$36K
86787		<1%	6,008	$36K
88342		<1%	1,625	$34K
82746		<1%	4,103	$33K
87529		<1%	742	$33K
84481		<1%	4,270	$32K
82627		<1%	1,920	$31K
86696		<1%	2,541	$30K
83516		<1%	2,771	$30K
83735		<1%	9,717	$30K
86376		<1%	2,824	$29K
82785		<1%	2,766	$29K
81001		<1%	12,693	$28K
86664		<1%	2,574	$27K
87088		<1%	4,379	$25K
86706		<1%	3,713	$25K
86663		<1%	2,579	$24K
86235		<1%	717	$23K
88304		<1%	1,370	$21K
86800		<1%	2,128	$20K
86900		<1%	8,669	$20K
82570		<1%	6,285	$20K
82950		<1%	5,388	$20K
86901		<1%	8,578	$19K
87338		<1%	2,122	$18K
86765		<1%	1,974	$18K
85651		<1%	9,401	$17K
86709		<1%	2,458	$17K
87205		<1%	6,528	$16K
83993		<1%	1,560	$15K
83690		<1%	3,580	$15K
84550		<1%	5,184	$15K
82105		<1%	2,423	$15K
87328		<1%	1,555	$15K
86431		<1%	3,819	$14K
86769		<1%	488	$14K
86694		<1%	2,181	$14K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	829	$13K
82550		<1%	3,404	$12K
84425		<1%	1,088	$12K
85730		<1%	2,640	$12K
84270		<1%	1,439	$12K
82043		<1%	3,481	$12K
83525		<1%	1,431	$12K
80074		<1%	880	$11K
82248		<1%	3,837	$11K
86735		<1%	1,861	$11K
84100		<1%	4,375	$11K
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	<1%	2,041	$11K
84165		<1%	1,846	$11K
82533		<1%	902	$11K
86318		<1%	2,790	$10K
80164		<1%	1,425	$10K
86704		<1%	1,547	$10K
86160		<1%	788	$10K
87075		<1%	1,408	$10K
82150		<1%	2,736	$10K
81003		<1%	7,775	$10K
82951		<1%	1,871	$10K
83615		<1%	2,881	$10K
84156		<1%	3,711	$9K
82565		<1%	2,905	$9K
84460		<1%	3,227	$9K
82947		<1%	2,770	$8K
82140		<1%	789	$8K
83498		<1%	401	$8K
86708		<1%	1,078	$8K
84450		<1%	2,959	$8K
86141		<1%	969	$8K
87324		<1%	1,097	$7K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	3,030	$7K
86617		<1%	341	$7K
86703		<1%	620	$7K
82103		<1%	770	$7K
80177		<1%	962	$7K
84480		<1%	1,186	$7K
86225		<1%	1,133	$6K
82977		<1%	1,660	$6K
85652		<1%	4,222	$6K
87329		<1%	870	$6K
88341		<1%	131	$6K
82747		<1%	612	$6K
87102		<1%	794	$6K
82247		<1%	1,814	$5K
87493		<1%	720	$5K
86705		<1%	853	$5K
85055		<1%	341	$5K
84703		<1%	2,059	$5K
83630		<1%	726	$5K
87081		<1%	1,111	$4K
84402		<1%	266	$4K
88112		<1%	225	$4K
84436		<1%	846	$3K
84155		<1%	1,559	$3K
82390		<1%	504	$3K
86200		<1%	1,169	$3K
84520		<1%	1,138	$3K
81596		<1%	75	$3K
80069		<1%	504	$3K
82040		<1%	1,065	$3K
83520		<1%	486	$2K
36415	Collection of venous blood by venipuncture	<1%	86,880	$2K
88173		<1%	98	$2K
87272		<1%	189	$2K
86255		<1%	421	$2K
86695		<1%	1,032	$2K
85379		<1%	278	$2K
87486		<1%	107	$2K
87581		<1%	107	$2K
82952		<1%	1,175	$2K
83010		<1%	178	$2K
86308		<1%	456	$2K
84999		<1%	2,230	$2K
85014		<1%	1,086	$1K
82330		<1%	251	$1K
85045		<1%	578	$1K
84166		<1%	156	$1K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	172	$1K
80175		<1%	157	$1K
85049		<1%	380	$919.42
80349		<1%	200	$874.44
80178		<1%	159	$830.64
84478		<1%	252	$773.28
82172		<1%	67	$732.65
87641		<1%	37	$682.27
86147		<1%	32	$611.85
87147		<1%	197	$578.17
82652		<1%	116	$537.14
84154		<1%	36	$533.88
86008		<1%	15	$515.78
84207		<1%	25	$515.23
86334		<1%	39	$507.84
88344		<1%	13	$488.84
86381		<1%	39	$437.87
83020		<1%	54	$437.27
85018		<1%	310	$399.00
83883		<1%	100	$387.79
86060		<1%	102	$385.24
86304		<1%	26	$382.96
82705		<1%	92	$319.13
84445		<1%	36	$303.81
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	12	$283.36
82104		<1%	27	$278.88
87106		<1%	44	$275.96
87177		<1%	49	$266.66
82653		<1%	26	$251.72
83718		<1%	295	$230.12
83721		<1%	710	$227.13
85007		<1%	132	$215.68
80162		<1%	30	$210.77
87269		<1%	15	$204.54
87040		<1%	25	$203.59
86671		<1%	45	$191.10
85046		<1%	82	$187.49
87209		<1%	37	$187.46
87109		<1%	26	$186.13
86666		<1%	14	$175.59
85613		<1%	26	$175.03
83918		<1%	12	$158.40
87149		<1%	30	$142.92
86015		<1%	27	$124.33
82465		<1%	44	$115.13
82365		<1%	13	$114.24
84484		<1%	16	$103.00
85246		<1%	13	$100.11
84132		<1%	29	$79.95
84432		<1%	30	$76.65
84591		<1%	26	$72.46
85048		<1%	51	$69.77
85384		<1%	14	$64.49
84134		<1%	14	$61.39
82270		<1%	25	$60.97
85660		<1%	34	$59.07
82656		<1%	17	$56.32
80325		<1%	12	$44.25
82310		<1%	13	$35.94
81015		<1%	12	$20.56
84075		<1%	26	$16.09
85041		<1%	12	$6.10
80361		<1%	15	$3.65
80365		<1%	15	$3.65

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialROMANO, RITA (CEO)